Human Interest
Reuters exclusively reported[1] that major African cocoa plants in Ivory Coast and Ghana have stopped or cut processing because they cannot afford to buy beans, meaning chocolate prices around the world are likely to soar.
Human Interest
Reuters exclusively reported[1] that major African cocoa plants in Ivory Coast and Ghana have stopped or cut processing because they cannot afford to buy beans, meaning chocolate prices around the world are likely to soar.
Deals
Reuters was first to report[1] on Southwest Airlines slashing its Boeing jet delivery forecast by more than 40%. The carrier’s shares tumbled nearly 15% in their worst day in nearly four years and the update highlighted ongoing pain in the airline
Read more https://www.reutersagency.com/en/reutersbest/article/southwest-cuts-delivery-forecast-from-boeing/
Business & Finance
Reuters exclusively reported[1] that Goldman Sachs Asset Management, a unit of Goldman Sachs Group, aims to expand its private credit portfolio to $300 billion in five years from the current $130 billion.
Goldman Sachs
Business & Finance
Reuters exclusively reported[1] that India’s Vishal Mega Mart is planning a $1 billion initial public offering that would value the budget supermarket chain at up to $5 billion with some of the proceeds earmarked to add stores.
Read more https://www.reutersagency.com/en/reutersbest/article/indias-vishal-mega-mart-planning-1-billion-ipo/
Business & Finance
Reuters exclusively reported[1] that Chinese billionaire entrepreneur and Olympic champion Li Ning is considering taking his namesake sportswear company private from the Hong Kong stock exchange, adding to a string of such potential deals
Energy
Reuters was first to report[1] that pipeline operator TC Energy’s Keystone oil pipeline suffered an outage which temporarily restricted the flow of crude through a major conduit of Canadian oil to the United States. Citing sources familiar with the
Read more https://www.reutersagency.com/en/reutersbest/article/tc-energy-keystone-oil-pipeline-outage/
Business & FinanceHealth
Reuters was first to report[1] on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares